Statins, a class of drugs predominantly targeting HMGCR, have emerged as potential candidates for the therapeutic intervention of Graves’ orbitopathy (GO), an autoimmune extrathyroidal manifestation in ~25-30% of Graves’ disease (GD) patients (49). This evidence concerns the gene HMGCR and Graves disease.